Phase II trial of second-line erlotinib and digoxin for nonsmall cell lung cancer (NSCLC)
Fadi Kayali, Muhamad A Janjua, Damian A Laber, Donald Miller, Goetz H KloeckerUniversity of Louisville, James Graham Brown Cancer Center, Louisville, KY, USABackground: In vitro digoxin sensitizes cancer cells to the induction of apoptosis by chemotherapy.Inhibition of the Na/K-ATPase enzyme by ouabain disturbs the intracellular ion composition of